News
Pfizer Strikes Deal With China's 3SBio
Digest more
The agreement comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital ...
Pfizer will pay China’s 3SBio $1.25 billion upfront to gain access to a cancer therapy that could rival Akeso and Summit’s ...
Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...
The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...
Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics ... If those results are positive the partners have said they could file for approval in the ...
Under the multi-year collaboration agreement, Guardant and Pfizer ... for its global clinical trials, which include China cohorts. In July 2022, Guardant announced a strategic partnership with ...
With the company’s Q1 2025 results on Tuesday, Pfizer (NYSE:PFE) indicated plans to explore acquisitions or partnerships to add cardiometabolic assets, including weight loss therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback